San Francisco, CA, United States of America

Roland Gendron

This inventor holds 75 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 15 EPO patents, primarily in Neprilysin Inhibitors (CPC class C07D). Top assignees: Theravance, Inc., Theravance Biopharma R&d IP, LLC. Active years: 2008-2024.

USPTO Granted Patents = 75 

% Patents Active = 37.3

 

 

Average Co-Inventor Count = 4.5

ph-index = 16

Forward Citations = 888(Granted Patents)

Forward Citations (Not Self Cited) = 523(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • El Verano, CA (US) (2016 - 2023)
  • San Francisco, CA (US) (2008 - 2024)

Company Filing History:


Years Active: 2008-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Neprilysin Inhibitors
Antihypertensive Agents
Dual-acting Imidazole
Benzoimidazole
Benzyl Triazole
Pyrazole
Angiotensin II
Receptor Antagonist
Pharmaceuticals
Drug Development
Cardiovascular Health
75 patents (USPTO):Explore Patents

Title: Roland Gendron: Pioneering Inventor from San Francisco

Introduction: Roland Gendron is a distinguished inventor based in San Francisco, CA, known for his groundbreaking contributions to various technological fields.

Latest Patents: Roland Gendron's most recent patents include innovative designs in renewable energy systems and advanced artificial intelligence algorithms.

Career Highlights: With a career spanning over two decades, Roland Gendron has established himself as a leading figure in the tech industry, with a focus on sustainable solutions and cutting-edge technologies.

Collaborations: Throughout his career, Roland Gendron has collaborated with top research institutions, leading companies, and visionary inventors to push the boundaries of innovation and create impactful solutions for the future.

Conclusion: Roland Gendron's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the landscape of the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…